Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)
January 16, 2024 16:30 ET
|
Cellectis Inc.
NEW YORK, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to...
Single Use Support continues to grow, expanding its team by 40%
January 16, 2024 07:45 ET
|
Single Use Support
The forecast for innovative process solution provider Single Use Support promises growth, exemplified by the addition of 40% more staff members.
Monthly information on share capital and company voting rights
January 08, 2024 16:30 ET
|
Cellectis Inc.
PARIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of sharesin the capitalTotal number of voting...
First Wave BioPharma Chairman and CEO Issues Letter to Shareholders Highlighting Recent Accomplishments and Outlook for 2024
January 04, 2024 06:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Jan. 04, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.8 Million Gross Proceeds Priced
December 27, 2023 11:55 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (“First Wave BioPharma” or the “Company”) (NASDAQ: FWBI), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Announces Streamlining of Clinical Pipeline with Non-Binding Term Sheet to Sell Niclosamide IBD Program
December 27, 2023 06:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 27, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023
December 22, 2023 16:30 ET
|
Cellectis Inc.
NEW YORK, Dec. 22, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving...
Rentschler Biopharma Announces Major Client Project for New U.S. Facility at Milford, MA Site
December 20, 2023 07:00 ET
|
Rentschler Biopharma SE
State-of-the-art Rentschler Biopharma Manufacturing Center (RBMC) facility slated to open for business next year LAUPHEIM, Germany and MILFORD, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Rentschler...
Kaplan Fox & Kilsheimer LLP Reminds Acelyrin Investors of a Class Action Lawsuit and Upcoming Deadline
December 17, 2023 08:01 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox reminds Acelyrin investors of a class action lawsuit and upcoming deadline.
EvolveImmune Therapeutics Provides Corporate and Program Update Highlighted by Closing of $37 Million Financing
December 13, 2023 07:00 ET
|
EvolveImmune
Fundraising Includes Strategic Investment by Bristol Myers Squibb Coupled with Support from Existing Investors EvolveImmune Initiates Chemistry, Manufacturing, and Control (CMC) Activities for Lead...